Clinical trials of type I and in vitro studies of type II immunoadsorbents for systemic lupus erythematosus therapy.
A highly selective immunoadsorbent was prepared by immobilization of DNA on carbonized resin beads (Type I) for the removal of the pathogenic antibodies of systemic lupus erythematosus (SLE) patients. Thirty cases of clinical trials of this SLE therapy were performed at 12 hospitals in China. The levels of anti-DNA antibodies after whole blood perfusion were decreased 40-70%. Almost all the symptoms were relieved, and some patients were freed from medicine administration. A new immunoadsorbent was prepared using aminated cellulose beads (Type II) having a higher DNA immobilization capacity of 0.6 mg/ml than the 0.4 mg/ml capacity for Type I. Stationary adsorption tests with the sera of SLE patients showed that the Type II immunoadsorbent could remove 60% of the pathogenic antibodies, which is much higher than the 30% for the Type I adsorbent.
Institute for Molecular Biology, Nankai University, Tianjin, China.
D L
DL
Kong
C Z
CZ
Chen
E F
EF
Lin
Y T
YT
Yu
D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D000936:Antigen-Antibody Complex / Q000097:blood; D002482:Cellulose; D002986:Clinical Trials as Topic; D005260:Female; D006464:Hemoperfusion; D006801:Humans; D007164:Immunosorbents / Q000627:therapeutic use*; D066298:In Vitro Techniques; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D008297:Male; D008863:Microspheres
D000974:Antibodies, Antinuclear; D000936:Antigen-Antibody Complex; D007164:Immunosorbents; D002482:Cellulose